Related references
Note: Only part of the references are listed.Loss of HER2 after HER2-targeted treatment
Tanja Ignatov et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W. Victoria Lai et al.
EUROPEAN JOURNAL OF CANCER (2019)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
Yelena Yuriy Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+(IHC3+) gastric carcinoma (GC).
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
Anna Dorothea Wagner et al.
BMC CANCER (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang et al.
ANNALS OF ONCOLOGY (2019)
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate
Yoriko Yamashita-Kashima et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters et al.
CLINICAL CANCER RESEARCH (2019)
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
In-Jae Oh et al.
CLINICAL LUNG CANCER (2018)
Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
Akitaka Makiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Kanika Bajaj Pahuja et al.
CANCER CELL (2018)
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
Hiroshi Saeki et al.
EUROPEAN JOURNAL OF CANCER (2018)
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Takamasa Koga et al.
LUNG CANCER (2018)
A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
J. Heymach et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition
Mei Hua Jin et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
Bernhard Kiss et al.
SCIENTIFIC REPORTS (2017)
Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101)
Satoshi Matsusaka et al.
GASTRIC CANCER (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Molecular characteristics of biliary tract cancer
Davendra P. S. Sohal et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.
Herbert Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Arlene Chan et al.
LANCET ONCOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
Juliana Eng et al.
LUNG CANCER (2016)
A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status
Hiroshi Yoshida et al.
VIRCHOWS ARCHIV (2016)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
M. G. Kris et al.
ANNALS OF ONCOLOGY (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites
Wafik S. El-Deiry et al.
CANCER BIOLOGY & THERAPY (2015)
Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2015)
HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
Rocco Cappellesso et al.
HUMAN PATHOLOGY (2015)
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer
Yelena Yuriy Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HER2/neu-directed therapy for biliary tract cancer
Milind Javle et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer
Tetsutaro Hayashi et al.
JOURNAL OF UROLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem et al.
GASTRIC CANCER (2015)
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab
Toru Kawamoto et al.
JOURNAL OF GASTROENTEROLOGY (2015)
Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
Juliann Chmielecki et al.
ONCOLOGIST (2015)
The emerging complexity of gene fusions in cancer
Fredrik Mertens et al.
NATURE REVIEWS CANCER (2015)
Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia-Pacific Task Force
Kyoung-Mee Kim et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014)
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
Y-K Kang et al.
BRITISH JOURNAL OF CANCER (2014)
HER-2/neu Gene Amplification in Relation to Expression of HER2 and HER3 Proteins in Patients With Esophageal Adenocarcinoma
Harry H. Yoon et al.
CANCER (2014)
Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib
Michela de Martino et al.
CANCER BIOLOGY & THERAPY (2014)
Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer
Akira Ema et al.
CANCER SCIENCE (2014)
A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
Jeffrey S. Ross et al.
CLINICAL CANCER RESEARCH (2014)
HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome
F. Ledel et al.
EUROPEAN JOURNAL OF CANCER (2014)
Molecular characterization of gallbladder cancer using somatic mutation profiling
Milind Javle et al.
HUMAN PATHOLOGY (2014)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
Akihiko Yoshizawa et al.
LUNG CANCER (2014)
Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway
Maolan Li et al.
NATURE GENETICS (2014)
Characterization of EGFR family gene aberrations in cholangiocarcinoma
Xiaoqing Yang et al.
ONCOLOGY REPORTS (2014)
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
An Na Seo et al.
PLOS ONE (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
Sumitra Mohan et al.
PLOS GENETICS (2014)
HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
Ralf Hofheinz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Large Cohort of Consecutive Patients Confirmed Frequent HER2 Positivity in Gastric Carcinomas with Advanced Stages
Junhun Cho et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
Jun Yang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis
Anna L. Paterson et al.
JOURNAL OF PATHOLOGY (2013)
Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
Eun Yoon Cho et al.
MODERN PATHOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
Petros D. Grivas et al.
MOLECULAR MEDICINE (2013)
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
A. Gallardo et al.
BRITISH JOURNAL OF CANCER (2012)
Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas
Harry H. Yoon et al.
CLINICAL CANCER RESEARCH (2012)
Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer
Yung-Jue Bang
JOURNAL OF CLINICAL GASTROENTEROLOGY (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
Hee Jin Lee et al.
VIRCHOWS ARCHIV (2012)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study
S. Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Guanglei Zhuang et al.
CANCER RESEARCH (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder
Nafis Shafizadeh et al.
HUMAN PATHOLOGY (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
EGFR and HER2 expression in advanced biliary tract cancer
Jan Harder et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Xiu Li Zhang et al.
WORLD JOURNAL OF SURGERY (2009)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
Kazuko Sakai et al.
CANCER SCIENCE (2007)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
Kaori Fujimoto-Ouchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers
K Nakazawa et al.
JOURNAL OF PATHOLOGY (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma
H Kalekou et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Low overexpression of HER-2/PPPNeu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin (R)) and irinotecan as therapy. A phase II trial
RK Ramanathan et al.
CANCER INVESTIGATION (2004)
HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder:: Prognostic implications
S Krüger et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
M Mann et al.
GASTROENTEROLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
